1. IPO dynamics
A shares
Trend:
From December 25th to 29th, a total of 4 companies were reviewed for IPO, and all 4 were approved. Among them, the Laplace Science and Technology Innovation Board has been approved;Lanyu Technology GEM has been approved;Wuxi Dingbang and Jin Zeli were approved by the Beijing Stock Exchange. In the first week of 2024 (January 2-5), Gangdi shares will be listed on the Shenzhen Stock Exchange and will be listed on the GEM.
IPO:
In the last week of 2023, a total of 5 new stocks in A-shares, including International Composite Materials, Dinglong Technology, Chenyi Intelligence, Laisai Laser, and Dali Cap, were listed, and the first day gains were respectively. 73%。
IPO Subscription:
In the last week of 2023, two new shares of A-shares, Jiezhong Technology and Bolong Technology, will be subscribed. In the first week of 2024, three new shares of A-shares are tentatively subscribed for subscription: Xueqi Electric, Xidian New Energy, and Yunxingyu.
Hong Kong stocks
On December 28, Anhui Conch submitted a prospectus to the Hong Kong Stock Exchange.
2. Hot spot tracking
Dairy company Junlebao listed counseling and filing, and officially launched the A-share IPO
On December 28, the Hebei Securities Regulatory Bureau** disclosed CICC's "Report on the Initial Public Offering and Listing Guidance of Junlebao Dairy Group Shares", and Junlebao officially started its A-share IPO journey.
Founded in 1995, Junlebao's business scope includes infant milk powder, yogurt, low-temperature fresh milk, room temperature liquid milk and dairy cow breeding, animal husbandry, grass industry and other sectors, and has built 25 production plants and 25 modern large-scale pastures in Hebei, Henan, Jiangsu, Jilin and other places.
In July 2022, Zhong Yan, vice president of Junlebao Dairy Group, said, "We have officially launched the IPO listing project and strive to complete the listing in 2025." He also said that in 2025, it will strive to achieve sales of 50 billion yuan, and Junlebao milk powder will become the world's leading brand of infant milk powder.
In January 2022, Junlebao spent 200 million yuan to acquire a 20% stake in Yunnan Lysil Dairy Co., Ltd., a subsidiary of Royal Group, and a 20% stake in Yunnan Lysil Intelligent Dairy, becoming the second largest shareholder of the above two companiesIn August of the same year, Junlebao signed a strategic cooperation agreement with Yinqiao Dairy to acquire the latter's core operating assets.
In May 2023, Junlebao signed a contract with Royal Group again to 32.9 billion yuan ** obtained 3289% equity and 3289% equity. After the completion of the two transfers, Junlebao holds 5790% equity and became the controlling shareholder.
In July 2023, Junlebao became the controlling shareholder of Yinqiao Dairy Technology, holding 80% of the sharesIn November, Junlebao signed a strategic cooperation agreement with the ready-made yogurt brand Mo Yogurt, and invested in the strategic investment of Mo Yogurt, holding 30% of the sharesIn December, Junlebao once again strategically invested in the probiotic company "Yiran Biotechnology", and the two sides will carry out all-round cooperation based on the scientific research innovation and industrialization layout of strains.
On December 15, 2023, Junlebao completed the share restructuring with a registered capital of 622160,000 yuan increased to 7200 million yuan, and at the same time, the business scope has added the production of formula food for special medical purposes. (The Paper).
Xiaohongshu responded to the listing rumors, and its net profit in 2023 may be $500 million
On December 25, it was reported that the social platform Xiaohongshu may launch a Hong Kong IPO in the second half of 2024, and before the IPO, Xiaohongshu plans to conduct another round of financing. In response, Xiaohongshu responded that the company currently has no plans to go public.
An investor close to Xiaohongshu said that Xiaohongshu plans to conduct another round of financing before launching the IPO, "basically a crossover round, and if it goes well, it will be closed in the first half of next year."
Tianyancha shows that Xiaohongshu has received 6 rounds of financing. In 2022's private market shares** deals, Xiaohongshu was valued at between $10 billion and $16 billion.
Xiaohongshu is rumored to record a net profit of $500 million in 2023, far exceeding the company's forecast of less than $50 million at the beginning of the year.
Since 2023, Xiaohongshu has continued to adjust its business lines and organizational structure, focusing on "buyer e-commerce" to obtain more advertising revenue from brands. At the same time, Xiaohongshu also cut its self-operated e-commerce business that was not profitable. (Company Research Office).
3. Problem warning
Nearly half of the revenue relied on the major shareholders to "pay", and the company withdrew its listing application
On December 27, the Shenzhen Stock Exchange** information showed that the initial public offering of Peptide Biotechnology was terminated and listed on the GEM for review.
In June 2023, the IPO application of Peptide Biotech was acceptedIn July, the company received the first round of review inquiry letter from the Shenzhen Stock Exchange, but the company has not replied to the inquiry letterIn September, due to the update of financial information, Peptide Biotech took the initiative to apply for the suspension of the issuance and listing review process.
Founded in 2015, Peptide Biotech is engaged in the research and development, production, sales and related services of peptide products. Peptide cosmetic raw materials are an important part of the company's operating income, and well-known cosmetics companies such as Proya, Bloomage Biotech, and Marubeni are all important customers of Papin Biotech.
From 2020 to 2022, the revenue of Peptide Bio will be 86.17 million yuan and 14.3 billion yuan, 21.5 billion yuan;The net profit was 1068860,000 yuan, 35.68 million yuan, 697640,000 yuan. Among them, in 2022, the tribute income of peptide cosmetic raw materials will be 13.8 billion yuan, accounting for 64 percent of the total revenue61%。
In 2022, the top five customers of Peptide Biotech are Proya, Bloomage Biotech, Shanghai Jiuqian Chemical, China Resources Shuanghe and Empower Clinic Services, Ll.c.。Among them, Proya, Bloomage Biotech, Shanghai Jiuqian Chemical, and China Resources Shuanghe are not only the main customers of Peptide Biotechnology, but also the shareholders of Peptide Biotechnology.
From 2020 to 2022, the revenue from the top five customers accounted for as a percentage of total revenue. 59%。(Blue Whale Finance).